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atheter Interventions for Hemodialysis
istulas and Grafts
ohn A. Bittl, MD
cala, Florida
ore than 1 in 1,000 patients in the U.S. has end-stage renal disease, and most patients who require
enal-replacement therapy undergo hemodialysis. By the year 2020, more than 750,000 patients are
xpected to have end-stage renal disease, and over 500,000 will require hemodialysis. The greatest
imitation of hemodialysis is the ﬁnite durability of hemodialysis accesses, which on average remain
atent for 3 years but are the lifeline for hemodialysis patients. Catheter-based interventions are suc-
essful in restoring ﬂow in more than 80% of hemodialysis accesses that undergo thrombosis and have
eplaced surgical revision as the treatment of choice for failing or thrombosed accesses. Catheter-
ased interventions have improved the quality of life for hemodialysis patients by reducing the need
or temporary hemodialysis catheters and have prolonged total survival time by preserving existing
ccess sites and by saving venous segments for future access creation. This review discusses the
athophysiology of dialysis access failure, presents the success rates of catheter-based treatments,
nd illustrates the interventional approaches for treating failing and thrombosed ﬁstulas and grafts.
J Am Coll Cardiol Intv 2010;3:1–11) © 2010 by the American College of Cardiology Foundationt
t
n
e
t
c
c
v
t
fi
A
o
T
a
v
p
f
w
p
s
rore than 350,000 persons require hemodialysis
or end-stage renal disease in the U.S., and by the
ear 2020, more than 750,000 patients are expected
o need renal-replacement therapy (1). With the
ising incidence of end-stage renal disease, the
reation of hemodialysis accesses has become the
ost commonly performed type of vascular surgery
2), but 50% of all hemodialysis accesses remain
atent for 3 years (3). Catheter-based interventions
re more than 80% successful in restoring flow each
ime thrombosis occurs and, after publication of
he Dialysis Outcomes Quality Initiative guidelines
n 1997 (4), catheter-based therapy has gradually
eplaced surgical revision as the treatment of choice
or failing or thrombosed fistulas and grafts. With
he rising number of patients requiring hemodial-
sis, the total outlay for maintaining hemodialysis
ascular access already exceeds $1 billion in the
.S. and is rising at more than 6% per year (5).
rom the Ocala Heart Institute, Munroe Regional Medical Center,
cala, Florida.aanuscript received August 11, 2009, accepted October 5, 2009.This report reviews the pathogenesis, indica-
ions, and outcomes for catheter-based interven-
ions for hemodialysis-access failure. Many tech-
iques illustrated in the review exist in the
ndovascular skill set and are readily adaptable for
reating failing or thrombosed hemodialysis ac-
esses. By using catheter-based therapies, endovas-
ular specialists fulfill a critical need by maintaining
ascular access patency for the vulnerable popula-
ion of hemodialysis patients, who consider their
stulas and grafts to be a lifeline.
natomy, Pathogenesis, and Incidence
f Access Failure
he identification of a suitable site for permanent
ccess placement depends on the adequacy of the
enous and arterial anatomy. The selection of a
articular access is based on evidence favoring the
ormation of an autogenous arteriovenous fistula
henever possible before resorting to the use of a
olytetrafluoroethylene (PTFE) graft (6–8). The
election of a particular location is based on the
ecommended sequence of using the nondominant
rm before the dominant arm, the forearm before
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2he upper arm, and the upper extremity before the lower
xtremity (2); but most hemodialysis patients ultimately will
ave functioning and failed access sites in multiple locations.
natomy. An autogenous arteriovenous fistula is surgically
ormed by directly anastomosing an endogenous artery to an
utflow vein. The pertinent venous anatomy in the upper
xtremity is straightforward and involves the basilic and
ephalic veins (Fig. 1). The basilic vein courses along the
edial aspect of the forearm, continues in the upper arm,
nd then courses into the axillary vein. The cephalic vein
rises along the lateral aspect of the forearm, continues in
he upper arm, and then drains into the axillary vein after
raversing the pectoral groove. The axillary vein continues as
he subclavian vein and then becomes the brachiocephalic
ein at the confluence of the internal jugular vein. The
onfluence of the right and left brachiocephalic veins defines
he origin of the superior vena cava.
The arterial anatomy of the upper extremity is similarly
traightforward (Fig. 2). The subclavian artery courses
nder the clavicle, becomes the axillary artery, and then
ecomes the brachial artery. The brachial artery divides into
he radial and ulnar arteries distal to the level of the
ntecubital crease.
Autogenous arteriovenous fis-
tulas have several different con-
figurations. In the forearm, the
common type is the Brescia-
Cimino radiocephalic fistula
constructed at the wrist between
the radial artery and the cephalic
vein (Fig. 3), usually in an end-
o-side configuration. Another configuration uses the prox-
mal radial artery anastomosed in a side-to-side manner
ith the median antebrachial vein (9). In the upper arm, the
asilic vein may be mobilized and tunneled laterally and
uperficially to form a transposed brachiobasilic fistula.
Prosthetic arteriovenous grafts also have several configu-
ations. An arm graft, which is created by surgically inter-
osing a PTFE connector between the brachial artery and
n arm vein, may have either a looped or straight configu-
ation. The most common forearm bridge-graft pattern is
he medial-to-lateral configuration of the brachiocephalic
raft (Fig. 3). The most common upper-arm bridge-graft
attern is the lateral-to-medial configuration of the brachio-
asilic graft. Other configurations involve a position in the
high in which a loop of PTFE is connected end-to-side
ith superficial femoral artery and end-to-end with the
reater saphenous vein.
athophysiology of access failure. Primary failure of an
utogenous arteriovenous fistula, defined as an access that
ever provided reliable hemodialysis after surgical creation,
ccurs in up to 50% of cases (10–14). Fistula failure is more
ommon in diabetic or elderly patients. In diabetic patients,
bbreviations
nd Acronyms
TA  percutaneous
ransluminal angioplasty
TFE  polytetrafluoroethylenehe patency of upper-arm brachiocephalic and transposed fiasilic vein fistulas at 18 months may be better than the
atency of forearm fistulas (78% vs. 33%) (15).
The failure of autogenous arteriovenous fistulas to mature
ithin several months of surgical creation has been attrib-
ted to several etiologies, but the presence of an inflow
tenosis caused by neointimal hyperplasia at the juxta-
nastomotic site (16) is a mechanism amenable to interven-
ional therapy (17–19). Percutaneous transluminal angio-
lasty of hypoplastic fistulas may increase blood flow, lead to
daptive remodeling, and allow hemodialysis to be carried
ut successfully (20).
The late failure of either autogenous arteriovenous fistulas
r prosthetic grafts is caused by the appearance of a stenosis
ithin an outflow vein that reduces flow and leads to
hrombosis. The underlying mechanism is the marked
ncrease in shear stress in the thin-walled outflow vein,
hich triggers focal fibromuscular hyperplasia and causes a
brotic venous lesion to appear (21,22). The pathogenic
tenoses causing access failure occur in various locations, but
he most common site in prosthetic arteriovenous grafts is at
he anastomosis between the graft and outflow vein, as
dentified in 47% (23,24) to 60% of cases (25), or in the
utflow vein itself in autogenous arteriovenous fistulas.
hen critical flow reduction and clotting ensue, the bulk of
he thrombus is probably red thrombus, which is rich in
Figure 1. Venous Anatomy of the Right Arm
Rt.  right; SVC  superior vena cava; v.  vein.brin and red cells and easily extracted with rheolytic
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3ethods or pulse-spray thrombolysis, but a platelet-rich
hite clot at the arterial anastomosis may require mechan-
cal removal with Fogarty thrombectomy in 35% to 60% of
ases to restore flow (23,26,27).
Although secondary thrombosis is a commonly associated
nding in failed hemodialysis accesses, primary thrombosis
f chronically used accesses is unusual. Primary thrombosis
ay be seen during the hypercoagulable state associated
ith hyperfibrinogenemia after major surgery or after pro-
ound hypotension associated with sepsis. Other nonana-
omic causes of access thrombosis are excessive post-dialysis
stula compression, polycythemia, hypovolemia, or throm-
ophilic conditions associated with Factor V Leiden or the
ntiphospholipid syndrome.
In summary, 2 modes of hemodialysis-access failure are
menable to interventional treatment (Fig. 4). In newly
laced fistulas, the development of an arteriovenous anas-
omotic stenosis prevents flow-mediated vasodilation, en-
argement, and maturation of the fistula. In chronically used
ccesses, the development of an outflow-vein stenosis causes
ow reduction, stasis, and thrombosis.
ncidence of access failure. Autogenous fistulas have a higher
Figure 2. Pertinent Arterial and Venous Anatomy of the Right Arm
a.  artery; Rt.  right.ate of primary failure than prosthetic grafts (50% vs. 15%),ut the long-term patency of fistulas is superior to that of
rafts. Autogenous fistulas fail after a median of 3 to 7 years,
hereas prosthetic arteriovenous grafts fail after a median
ifetime of only 12 to 18 months (28–31). For this reason,
rofessional societies from several countries recommend an
utogenous fistula as the access of choice for hemodialysis
6–8).
igns of Access Failure
he National Kidney Foundation–Dialysis Outcomes
uality Initiative (32) recommends an organized program
o identify failing fistulas and grafts. Monitoring is carried
ut with regular physical examinations and assessment of
ialysis adequacy. Surveillance refers to the performance of
oninvasive testing to gather further information about
ccess structure and function. Diagnostic testing refers to
he performance of procedures, usually invasive, to define
ccess anatomy and hemodynamics.
onitoring. Physical examination performed on a weekly
asis by nephrologists can identify the presence of inflow or
utflow stenoses in hemodialysis accesses. The mature
Figure 3. Composite Illustration of Access Anatomy of the Right Arm
The commonly used conﬁgurations are shown for an autogenous radioce-
phalic ﬁstula and for prosthetic brachiocephalic and brachiobasilic grafts.
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4stula or graft should course conspicuously in the subcuta-
eous tissue and have a prominent thrill and continuous
edium-pitched bruit similar to the continuous murmur of
patent ductus arteriosus. Disappearance of the thrill and
ruit is diagnostic of hemodialysis-access thrombosis.
Increased post-dialysis bleeding suggests the presence of an
utflow stenosis. A prominent pulsation over the access is
bnormal and may signify elevated pressure within the access
aused by an outflow stenosis. This may be accompanied by a
hange in the bruit on serial examinations from a continuous
edium-pitched bruit to a short high-pitched bruit. Multiple
neurysmal segments in the distribution of a large, mature,
erpiginous fistula or graft used for many years may actually be
seudoaneurysms caused by impaired hemostasis and chronic
enous hypertension. Marked fibrotic venous wall thickening
ay produce palpable subcutaneous nodules anywhere along
he course of an outflow vein.
Marked arm edema usually indicates dual venous obstruc-
ion in both the cephalic and basilic veins or an isolated
cclusion of a central vein related to prior central venous
atheter placement in the axillary, subclavian, or brachioce-
halic veins or in the superior vena cava. Depending on the
evel of central venous obstruction, this may be accompanied
y the development of facial plethora or extensive venous
ollateral veins on the arm or chest wall.
The inability to insert dialysis needles into a patent but
ypoplastic fistula or the finding of a soft bruit and fine thrill
ver a recently created fistula may indicate the presence of
n anastomotic inflow stenosis. The coexistence of inflow
nd outflow stenoses may produce mixed physical findings,
alanced hemodynamics, and difficult needle entry for
emodialysis.
nfection. Signs of infection are indicated by the presence of
ellulitis, fluctuance, skin breakdown, or purulent discharge.
ild isolated erythema without tenderness or edema is usually
Figure 4. Pathogenesis of Hemodialysis-Access Failure
The early appearance of an inﬂow anastomotic stenosis may impair ﬁstula
maturation. The late development of a stenosis in the outﬂow segment of
a ﬁstula or graft may cause stasis and thrombosis.ot a sign of infection, but uremia may mask fever or eeukocystosis. Anorexia, weight loss, and myalgias may be
onstitutional symptoms suggestive of infection. Access
nfection is a contraindication to interventional treatment
ecause of the resistance of infected thrombus to endovas-
ular therapies and the risk of sepsis.
urveillance. Hemodynamic surveillance should prompt re-
erral for angiographic evaluation if dynamic venous pres-
ures on hemodialysis exceed 120 mm Hg, fistula flow falls
o 500 ml/min, graft flow decreases to 650 ml/min, or
ccess blood flow falls by more than 25%. Evidence of
ncomplete dialysis may be suggested by the recirculation
raction using urea concentrations or clinical parameters
uch as body weight, volume status, or serum potassium
oncentration, but these are probably relatively late predic-
ors of graft failure and become abnormal at the time of
mpending thrombosis (8). The observation of rising pres-
ures 340 cm H2O at a constant flow of 200 ml/min may
lso indicate the presence of an outflow stenosis (8). The
nthusiasm for regular ultrasonographic surveillance for
arly detection of access failure (33) has been tempered by
he expense, limited availability, and high likelihood of
xcessive referral for invasive testing (32).
re-emptive invasive evaluation. The ability of early an-
iography and pre-emptive angioplasty to prevent access
hrombosis remains uncertain. In 1 study (34) of 21 patients
ith prosthetic arteriovenous accesses that had not previ-
usly clotted or required intervention, pre-emptive angio-
lasty reduced the risk of thrombosis from 44% to 10% per
00 patient-years (p  0.01). Another study (35) reported
hat prophylactic angioplasty (n  32) was superior to the
tandard treatment of fistulas (n  30) in reducing throm-
osis rate from 25% to 16% per 100 patient-years. Tessitore
t al. (36) evaluated the cost-effectiveness of access blood-
ow measurements and pre-emptive angioplasty in 159
atients and observed that a 3-fold increase in the number
f angiographic procedures offset a 77% reduction in throm-
osis events and a 65% reduction in fistula loss, thus
efining an “economically dominant therapy” (i.e.,
ost-saving).
Several randomized studies have suggested that early
ngiography fails to prevent access thrombosis. A prospec-
ive randomized trial (37) of 64 patients monitored with
onthly static venous-to-systolic blood pressure ratios com-
ared prophylactic angioplasty with the strategy of delayed
nvasive management at the time of thrombosis and ob-
erved similar rates of thrombosis rates and access loss (37).
nother randomized trial (38) of 112 patients compared
onthly access blood-flow measurements with standard
urveillance and reported that the greater number of inter-
entions performed in the surveillance group than in the
ontrol group did not reduce the rate of access thrombosis
41% vs. 51% per 100 patient-years, p  NS). A recent
conomic analysis (39) has suggested that early angiography
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5nd pre-emptive percutaneous transluminal angioplasty
PTA) produced a decline in access thrombosis from 27.6 to
2.0 events per 100 patient-years (p  0.029) but the net
ost was $34,586 per 100 patient-years and the incremental
ost-effectiveness ratio for invasive surveillance was $6,177
er thrombosis event avoided. The Vascular Access Work
roup has concluded that as a preventive strategy, “there is
onsiderable debate concerning whether PTA interventions
mprove long-term outcomes” (40).
nterventional Therapy
ngiographic evaluation is generally recommended if mon-
toring or surveillance suggests that thrombosis either is
mminent or has already occurred. The inability to insert
ialysis needles in patent but hypoplastic fistulas is an
ndication for angiographic evaluation. Access thrombosis
hould trigger urgent angiographic referral before a single
emodialysis treatment is missed (Table 1). Contraindica-
ions to angiographic management of thrombosed accesses
nclude the presence of a right-to-left intracardiac shunt,
ulmonary hypertension, infected access, or surgical revision
30 days before referral.
nterventional procedure. The approach for thrombosed
stulas and grafts requires a sequential series of endovascular
rocedures (Table 2). Percutaneous needle entry into the
ccluded fistula or graft is straightforward, even though no
ashback of blood occurs and no contrast or saline can be
njected. The clotted access is ballotable. The usual entry
ites are characterized by thickened skin and healing needle
racks. If a guidewire cannot advance easily through an
8-gauge thin-wall needle, an alternative approach is to
nter the graft with a 4-F micropuncture set (Cook, Inc.,
loomington, Indiana) and exchange for a full-size sheath.
n either case, a distinct “pop” is felt when the dura is
enetrated with a needle. It is important to avoid punctur-
ng the back wall of the graft because an external hematoma
ay compress the access.
The accompanying figures illustrate the standard throm-
ectomy methods for prosthetic arteriovenous grafts, but
he techniques are immediately transferable for declotting
utogenous fistulas as well. The procedure is begun by
lacing two 6-F sheaths within the access, 1 in the direction
Table 1. Specific Indications for Catheter Intervention of
Hemodialysis Accesses
Early failure of hypoplastic autogenous arteriovenous ﬁstulas
Inﬂow stenosis at the arteriovenous anastomosis
Early development of venous outﬂow stenosis
Late failure of chronic ﬁstulas and grafts
Access thrombosis (urgent)
Isolated venous or outﬂow anastomotic stenosis
Arm edemabCentral vein or double outlet stenosisf the arterial inflow and the other in the direction of the
enous outflow (Fig. 5). The term “cross-sheath technique”
s commonly used but misleading because the tips of the
heaths face each other but do not overlap. Thrombus
ithin a segment of overlapping sheath tips would be
naccessible to catheter thrombectomy.
Advancement of 0.018-inch hydrophilic guide wires
V18, Boston Scientific, Natick, Massachusetts) in the
utflow and inflow directions provides tracks for the cath-
ters needed for thrombectomy and treatment (Fig. 5). If it
s difficult to identify or penetrate the outflow venous
tenosis with the 0.018-inch guidewire or to enter the
nflow artery using fluoroscopy alone, replacement of the
ire with a 5-F multipurpose catheter for limited angiog-
aphy is useful. Large amounts of contrast must never be
njected into a clotted access because thrombus will protrude
nto the inflow artery and embolize distally to the hand.
fter limited angiography is performed, penetration of the
esistant stenosis can usually be achieved with a 0.035-inch
ydrophilic curved wire and then replaced with the 0.018-
nch guidewire for thrombectomy.
tep 1: thrombectomy. Various mechanical and thrombo-
ytic approaches are available to declot thrombosed accesses.
he devices include pulse-spray infusion catheters (Cook,
nc.), pulse-spray side-slit catheters (Angiodynamics, Inc.,
lens Falls, New York), the Amplatz Thrombectomy
evice (Microvena, White Bear Lake, Minnesota), the
rrow-Trerotola Percutaneous Thrombectomy Device (Ar-
ow International, Reading, Pennsylvania), and the Gelbfish
ndo-Vac device (Neovascular Technology, New York,
ew York). Rheolytic thrombectomy with the Possis An-
ioJet (Possis Medical, Minneapolis, Minnesota) is popular
ecause of its widespread availability in cardiac catheteriza-
ion laboratories and its rapid ability to declot grafts with
he 60-cm, AngioJet AVX catheter (Possis Medical).
Rheolytic thrombectomy should be performed first in the
irection of venous outflow (Fig. 6). This is immediately
ollowed by thrombectomy in the direction of the arterial
nflow (Fig. 7). If the blunt facing tip of 1 sheath prevents
atheter advancement, insertion of sheath dilator presents a
moother transition for advancing the thrombectomy
atheter.
tep 2: angiography and angioplasty. After flow is achieved,
he access sheaths are flushed clear with saline and the
athogenic stenosis can be identified using angiography
Fig. 8). Venous PTA in the arm requires 6- to 10-mm
Table 2. The 4-Step Approach for Thrombosed Hemodialysis Fistulas
and Grafts
1. Thrombectomy of outﬂow and inﬂow segments
2. Angiography of ﬁstula or graft and central veins
3. Percutaneous transluminal angioplasty of venous outﬂow stenosis
4. Fogarty thrombectomy of adherent clot at the arterial inﬂow anastomosisalloons. Venous stenoses are characterized by extensive
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6brosis and the need for ultra-high pressure balloon infla-
ions (41) or cutting balloon atherotomy for optimal treat-
ent (42–44). High-pressure, noncompliant balloons
Conquest or Dorado, Bard Peripheral Vascular Inc.,
empe, Arizona) with rated burst pressures of 20 to 24 atm
an be used. Cutting Balloons (Boston Scientific) can be
sed when high-pressure balloons are unsuccessful (42–44),
ut the use of a peripheral cutting balloon device in 1 study
45) was associated with an increased risk of rupture.
tep 3: Fogarty thrombectomy. An important step to restore
dequate flow involves the use of mechanical thrombec-
omy. The over-the-wire 4-F Fogarty Thru-Lumen Embo-
ectomy Catheter (Edwards Lifesciences, Irvine, California)
s almost always required to extract resistant thrombus from
he arterial inflow (Fig. 9). After the embolectomy catheter
as been used, the disrupted thrombus lodges against the
heaths and can be removed with rheolytic thrombectomy.
ulmonary embolization is rarely encountered. Petronis et
l. (46) observed no scintigraphic evidence of pulmonary
mbolism in a systematic evaluation of patients after phar-
acologic and mechanical declotting of thrombosed hemo-
Figure 5. Facing-Sheaths Technique for Thrombosed Prosthetic Grafts
A 6-F sheath is inserted into the access near the arterial anastomosis and
directed into the direction of the outﬂow, and a 6-F sheath is inserted into
the access near the venous anastomosis in the direction of the inﬂow.
Guidewires are advanced in the direction of the inﬂow and outﬂow under
ﬂuoroscopic guidance. No contrast is injected into a thrombosed access.
Abbreviations as in Figures 1 and 2.ialysis accesses.The problem of persistent thrombosis and no reflow after
reatment is challenging but may be successfully treated
ith repeated passes with Fogarty embolectomy catheter
hrough the inflow anastomosis. The catheter must be
ithdrawn forcefully to dislodge the resistant inflow throm-
us. If this fails and pressure within the access remains low,
TA of the arterial inflow anastomosis with a 6-mm
alloon can be tried. Another cause of low fistula or graft
ressure is a stenosis within the native radial or brachial
rtery, which may be amenable to PTA.
tep 4: central venography. The final step entails venogra-
hy of the outflow and central veins. This is necessary to
ule out the presence of a central stenosis that may have
een caused by the previous use of hemodialysis catheters.
owever, treatment of incidental central vein stenoses
emains controversial. Levit et al. (47) evaluated the success
f pre-emptive angioplasty or stenting for central venous
tenoses ipsilateral to hemodialysis accesses in 35 patients
ho underwent 86 angiograms over a 6-year period. An-
ioplasty or stenting of asymptomatic stenoses was associ-
ted with more rapid stenosis progression and escalation of
esions than the strategy of watchful waiting. If central
enous stenoses are clinically significant and causing arm
dema (Fig. 10), they may be suitable for treatment with
arge-diameter devices such the XXL balloon (Boston Sci-
Figure 6. Thrombectomy of Outflow Segment
The AngioJet AVX catheter (Possis Medical) is activated and advanced over
the guidewire in the direction of the venous outﬂow and then withdrawn
at a rate of 1 mm/s. Abbreviations as in Figures 1 and 2.
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7ntific Medi-Tech, Natick, Massachusetts), the high-
ressure Atlas balloon (Bard Peripheral Vascular), the
entinol Self-Expanding Nitinol Biliary Stent System or
he Wallstent RX Biliary Endoprosthesis (both from Bos-
on Scientific Corporation).
inal steps. At the end of the procedure, the decision
emains whether to proceed with adjunctive stenting of the
athogenic stenosis in the outflow vein. In general, stenting
rovides no clear benefit over PTA alone and eliminates the
ption of using the stented vein for future surgical revision.
tents are thus reserved for severe recoil, venous perfora-
ions, or stenoses in surgically inaccessible veins. In a series
f 65 patients treated with self-expanding stainless steel
tents for failing or occluded dialysis accesses (48), repeat
hrombosis occurred in 10% of patients within 1 week. In a
eries of 52 patients (49), the primary patency at 6 months
as only 46% after placement of stents. Another study
uggested that the provisional use of stents could success-
ully salvage failed PTA procedures (23). More studies are
eeded to determine whether nitinol or covered stents have
etter long-term patency than stainless steel stents (50,51).
The final pressure achieved in the access may determine
ong-term success. Access pressures that are significantly
Figure 7. Thrombectomy of Inflow Segment
The AngioJet catheter (Possis Medical) is activated and advanced over the
guidewire in the direction of the arterial inﬂow and then withdrawn.
Abbreviations as in Figures 1 and 2.igher than one-third of systemic pressure are associatedFigure 8. Angioplasty of Stenosis
After ﬂow has been restored, angiography of the entire graft can be com-
pleted. The stenosis causing stasis and thrombosis of the graft can be iden-
tiﬁed and treated with balloon angioplasty. Abbreviations as in Figures 1Figure 9. Fogarty Thrombectomy of Resistant Thrombus
A 4-F over-the-wire Fogarty catheter is advanced into the brachial artery
beyond the resistant inﬂow stenosis, and the balloon is inﬂated (A). The
catheter is forcefully withdrawn (B), dislodging the resistant thrombus (C).
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8ith lower rates of long-term patency than lower access
ressures (23,52).
At the conclusion of the procedure with demonstration of
widely patent graft with excellent flow, intradermal
-sutures are placed and tightened to control bleeding after
heath withdrawal. Sutures are removed in 1 to 4 days.
djunctive pharmacology. The medical management during
nvasive treatment is minimal. Aspirin 325 mg is given orally
efore the procedure. For thrombosed accesses, heparin 5,000
is given intravenously during the procedure. For nonthrom-
osed accesses, lower doses of heparin can be considered,
Figure 10. Central Venous Stenting
Recurrent restenosis after repeat balloon angioplasty caused by the presence o
and venous collaterals (A), which were no longer visible after stent implantatio
Figure 11. Success Rates
In a consecutive series of 1,437 angiographic procedures, the success of cath
30 days without repeat angiography or surgical revision.specially if the risk of bleeding or perforation is increased, as
n newly placed unused fistulas. Antibiotic prophylaxis with
efuroxime 1 g intravenously is recommended. Vancomycin
g intravenously over 0.5 h can be used if an allergy to
ephalosporins exists. Warfarin is recommended for the sec-
ndary prevention of access thrombosis if no stenosis is found.
uccess Rates and Complications
n a recent series (39), catheter-based interventions (Fig. 11)
esulted in successful hemodialysis for at least 30 days
brillator leads ipsilateral to a ﬁstula was associated with marked arm edema
. v.  vein.
ased interventions is shown resulting in successful hemodialysis for at leastf deﬁeter-b
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9ithout repeat angiography or surgical intervention in 1,317
f 1,437 procedures (92%). The angiographic success rate
as lower for thrombosed fistulas than for thrombosed
rafts (80% vs. 94%, p  0.001). Beathard (53) reported
-month patency rates of 61% and 1-year patency rate of
8% after a variety of catheter interventions by interven-
ional nephrologists. Several studies (39,54) have shown that
utogenous arteriovenous fistulas tend to have longer median
atencies than prosthetic grafts after catheter-based inter-
ention (Fig. 12). However, a history of access thrombosis
mpairs long-term patency and reduces the advantage of
utogenous arteriovenous fistulas over prosthetic grafts so
hat both types of accesses have similar patency durations of
bout 3 months after declotting (23).
omplications. Catheter treatment of hemodialysis accesses is
enerally safe. Complications can be categorized as Grade I
ematomas (minor, nonflow-limiting), Grade II hematomas
flow-limiting), or Grade III hematomas and perforations (55).
essel rupture and free perforation have been identified as
otential catastrophic complications of percutaneous treatment
45,56–60) and occur in 1% of cases. One study (45)
uggested that using a balloon catheter more than 2 mm larger
han the diameter of the hemodialysis access or using periph-
ral cutting balloons increased the risk of rupture or perfora-
ion. In some cases of rupture, complete hemostasis requires
he insertion of the Fluency Plus Tracheobronchial Stent Graft
Bard Peripheral Vascular), a polyethylene teryltolate-covered
tent (WallGraft, Boston Scientific), or a Viabahn Endopros-
hesis (W.L. Gore and Associates, Flagstaff, Arizona), after
Figure 12. Duration of Access Patency
Kaplan-Meier analysis of patency after percutaneous intervention is pre-
sented for 611 autogenous arteriovenous ﬁstulas and 699 prosthetic grafts
undergoing pre-emptive angioplasty or thrombectomy for thrombosis.witching to 10- or 11-F sheaths (Fig. 13).uture Directions
edical therapy. Several randomized trials of antithrom-
otic agents to prevent thrombosis have been reported, but
one has been unequivocally successful in preventing
hrombosis of dialysis accesses. In a randomized trial of 877
atients (10), clopidogrel was no better than placebo for
llowing autogenous arteriovenous fistulas to be used suc-
essfully for hemodialysis (38% vs. 40%). In another ran-
omized trial of 649 patients (14), dipyridamole was mod-
stly better than placebo in achieved primary unassisted
atency of autogenous arteriovenous fistulas at 1 year (28%
s. 23%).
Several experimental methods under investigation have
een designed to enhance the long-term patency of arterio-
enous grafts by targeting intimal hyperplasia in the venous
Figure 13. Venous Rupture
Dilation of a stenosis in the basilic vein (A, arrow) was followed by free
rupture and extravascular contrast (B, arrows) and successfully treated
with a covered stent (C).
o
s
l
b
a
v
g
m
t
t
p
S
T
h
c
y
c
c
t
i
c
l
A
T
J
R
S
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 , 2 0 1 0
J A N U A R Y 2 0 1 0 : 1 – 1 1
Bittl
Dialysis Access Interventions
10utflow. External beam radiation has been tried, but in
mall series of patients this was unable to reduce the
ikelihood of repeat restenosis (61).
The use of endothelial cell seeding of PTFE grafts is
ased on the concept that these cells can form a biologically
ctive lining and reduce the release of mitogens that lead to
ascular smooth muscle proliferation. Lining of PTFE
rafts with anti-CD34 antibodies, which bind bone
arrow-derived circulating CD34() endothelial progeni-
or cells, resulted in almost complete endothelialization of
he grafts but paradoxically increased in neointimal hyper-
lasia at the graft-vein anastomosis (62).
ummary
he catheter-based treatment of thrombosed and failing
emodialysis accesses achieves success in more than 80% of
ases and allows patients to undergo immediate hemodial-
sis without the need for placement of temporary dialysis
atheters or surgical consumption of additional venous
onduits. Life on hemodialysis can be a Hobbesian exis-
ence—“nasty, poor, brutish, and short”—but the availabil-
ty of catheter-based approaches within many medical
enters has preserved a lifeline and improved the quality of
ife for hemodialysis patients.
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